A process for preparing human adipose stem cell preparation and its application

Through the human fat stem cell preparation process, combined with the fermentation products of wolfberry, tea and beetroot, the immune rejection reaction problem that facial skin aging treatment cannot physiologically anti-aging and fat stem cell application in the prior art is solved, and internal and external properties are achieved Anti-aging and lowering blood pressure effects.

CN118750654BActive Publication Date: 2024-12-03WESTERN MEDICAL BEAUTY BIOTECHNOLOGY CHENGDU CO LTD SHUANGLIU MEDICAL BRANCH
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202411250846.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

The prior art cannot be physiologically anti-aging in facial skin aging treatment, and the application of adipose stem cells has problems of immune rejection and difficulty in obtaining.

Method used

The human fat stem cell preparation process is adopted, and the injection agent with anti-aging and lowering blood pressure effects is prepared through activation, culture, suspension preparation and co-fermentation of bacterial fluid, combined with the fermentation products of wolfberry, tea and beetroot.

Benefits of technology

The combination of endogenous and exogenous anti-aging is achieved, which reduces immune rejection, improves cell repair ability, and has significant anti-aging and blood pressure-lowering effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118750654B_ABST
    Figure CN118750654B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and mainly relates to a fat stem cell process, and specifically to a process for preparing a human fat stem cell preparation and its clinical application. The present invention uses a fat stem cell suspension that is easily available and has a low immune rejection reaction, and mixes the fermentation supernatant obtained by aerobic and anaerobic synergistic fermentation of wolfberry, tea and beetroot to obtain a fat stem cell anti-aging injection, and uses fat stem cells to improve the vitality of damaged cells and antagonize cell apoptosis, and has the effects of promoting angiogenesis and tissue repair for endogenous anti-aging. At the same time, combined with the anti-ultraviolet effects of wolfberry polysaccharides, tea polyphenols and nicotinamide riboside in the fermentation product, it performs exogenous anti-aging, which is of great significance to the medical beauty industry related to skin anti-aging.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and mainly relates to an adipose stem cell process, and specifically to a process for preparing a human adipose stem cell preparation and its clinical application. Background Art

[0002] Skin is the largest organ in the human body. It is the door to resist the invasion of harmful substances from the outside world and prevent the loss of water in the body; it is also a window to reflect the physiological state, pathological state and even psychological state of the human body. Skin aging is a complex aging process caused by multiple endogenous and exogenous factors. Modern medicine divides skin aging into intrinsic aging and photoaging. Skin aging caused by endogenous factors is an inevitable natural process, called natural aging, intrinsic aging, and physiological aging; exogenous factors mainly refer to the influence of environmental factors, including ultraviolet rays, dust, climate, etc. Skin is the most obvious indicator of age. When the body ages, the skin also ages. Skin aging can have obvious clinical manifestations, which not only affects the appearance, but also gives people great psychological pressure, seriously affecting normal life and study.

[0003] In recent years, people's demand for facial beauty and anti-aging has been increasing, and various methods for treating facial skin aging have emerged one after another. The facial rejuvenation technologies currently used in clinical practice mainly include: face lifting surgery, hyaluronic acid filling, botulinum toxin injection, chemical peeling and physical grinding, which can achieve certain effects in the treatment of facial skin rejuvenation. However, these methods only achieve the effect of beautifying the appearance of the skin, and cannot truly achieve the effect of anti-aging from a physiological perspective. With the widespread development of stem cell research, adipose-derived stem cells (ADSCs) have entered the field of vision of researchers as a very effective anti-aging material. Adipose stem cells can enhance the vitality of cell proliferation and migration, improve the vitality of damaged cells, antagonize cell apoptosis, promote angiogenesis, tissue repair, and inhibit tissue inflammatory response. They have a significant application effect in the field of anti-aging. Summary of the invention

[0004] In view of the shortcomings of the existing technology and the excellent performance of adipose stem cells, the present invention uses human adipose stem cell technology and preparations for skin anti-aging.

[0005] In a first aspect, the present invention provides a process for preparing a human adipose stem cell preparation, which specifically comprises the following steps:

[0006] S1. Activation and culture of adipose-derived stem cells (ADSCs): Take out the frozen adipose-derived stem cells from liquid nitrogen or -80℃ freezer, quickly put the cryotube into a 37℃ water bath to thaw quickly until only a few ice crystals remain, transfer the thawed cells into a centrifuge tube containing 5-10 times the volume of the culture medium, i.e. LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin, centrifuge at 1200-1500 r / min for 5 min to remove the cryosol containing DMSO, then resuspend the cells in LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin, and centrifuge at 3×10 6 -4×10 6 The cells were inoculated into T25 culture flasks at a cell density of 100 cells / ml and cultured in an incubator at 37°C and 5% CO2. After 72 hours of culture, the medium was replaced for the first time, and then the medium was replaced every 3 days until the primary cell confluence reached 80%-90%. Then, the cells were digested with 0.25% trypsin and passaged at a ratio of 1:3.

[0007] S2. Preparation of adipose-derived stem cells (ADSCs) suspension: 2×10 3rd generation ADSCs with good growth conditions were taken. 7 -3×10 7 1×10 6 The cells were inoculated into T25 flasks at a density of 10 cells / ml. When the cell confluence reached 70-80%, they were digested with 0.05% trypsin to form a cell suspension and counted. After centrifugation at 1000 r / min for 5 minutes, they were resuspended in 0.5 ml of PBS solution. The final cell concentration was adjusted to 2×10 6 / ml for standby use;

[0008] S3. Preparation of bacterial solution: The concentration is 3.1×10 9 -5.2×10 9 cfu / ml of Lactobacillus plantarum AS1.555 (Wuhan Huaerna Biotechnology Co., Ltd., Catalog No.: N-16972, aerobic) bacterial solution and a concentration of 2.2×10 9 -4.1×10 9 cfu / ml of Bifidobacterium breve ATCC 15701 (Beijing Bio-Bowei Biotechnology Co., Ltd., catalog number: bio-67242, anaerobic) bacterial solution for standby use;

[0009] S4, the wolfberry, tea and beetroot are crushed and mixed, and then mixed with Bifidobacterium breve ATCC 15701 bacterial solution and deionized water in a mass ratio of 3-5:0.2-0.7:5-10, and then fermented in a cylinder, and the anaerobic fermentation is carried out at a temperature of 35-37°C and a fermentation time of 6-12 hours; then the plant lactobacillus AS1.555 bacterial solution with the same mass as the Bifidobacterium breve ATCC 15701 bacterial solution is added, and aerobic fermentation is carried out at a temperature of 35-37°C and a fermentation time of 6-12 hours. After the fermentation is completed, 3% hydrogen peroxide is added to inactivate Bifidobacterium breve ATCC 15701 and Lactobacillus plantarum AS1.555, and then centrifuged at 8000r / min for 10min, and the supernatant is collected. The obtained supernatant is sent to a steam sterilizer for sterilization at 121°C for 15min, and the sterilization program is: 10°C / min, raised to 121°C, kept at 121°C for 15min, and cooled naturally after the program ends;

[0010] S5, the adipose stem cell suspension prepared in step S2 was mixed with physiological saline containing 5% by volume of umbilical cord blood plasma to a concentration of 5×10 5 / ml, take 1ml of the adjusted concentration of adipose stem cell solution and mix it with the fermentation supernatant prepared in step S4 with a volume fraction of 20-50% of the adipose stem cell solution, and place it in an ampoule to obtain adipose stem cell injection. Among them, umbilical cord blood plasma (Human Cord Blood Plasma), item number ABC-TC3386, was purchased from Beijing Bio Innovation Technology Co., Ltd.

[0011] Preferably, the adipose-derived stem cells cryopreserved in step S1 of the present invention are primary adipose-derived stem cells from sheep (purchased from Wuhan Saios Biotechnology Co., Ltd., product number PC-016shp).

[0012] Preferably: in step S1 of the present invention, 4×10 6 The cells were seeded into T25 culture flasks at a cell density of 10 cells / ml.

[0013] Preferably, in step S2 of the present invention, 2×10 3rd generation ADSCs with good growth conditions are taken. 7 1×10 6 The cells were inoculated into T75 flasks at a density of 10 cells / ml.

[0014] Preferably: the concentration prepared in step S3 of the present invention is 4.1×10 9 cfu / ml of Lactobacillus plantarum AS1.555 bacterial liquid.

[0015] Preferably: the concentration prepared in step S3 of the present invention is 3.2×10 9cfu / ml of Bifidobacterium breve ATCC15701 bacterial solution.

[0016] Preferably, in step S4 of the present invention, wolfberry, tea leaves and beetroot are crushed and mixed in a mass ratio of 1:1:2.

[0017] In a second aspect, the present invention provides a preparation obtained by the process of the above-mentioned human adipose stem cell preparation.

[0018] In a third aspect, the present invention provides the use of the above-mentioned preparation in anti-aging and lowering blood pressure.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] 1. The present invention uses adipose stem cells to prepare injections, which are easier to obtain than other stem cells, such as bone marrow stem cells and umbilical cord mesenchymal stem cells.

[0021] 2. Compared with other types of stem cells, the adipose stem cells used in the present invention have lower immunogenicity, which reduces immune rejection reactions when used in allogeneic ways.

[0022] 3. The present invention combines endogenous and exogenous anti-aging effects. Adipose stem cells are used to improve the vitality of damaged cells, antagonize cell apoptosis, promote angiogenesis, and repair tissues for endogenous anti-aging. At the same time, the anti-ultraviolet effects of wolfberry polysaccharides, tea polyphenols, and nicotinamide riboside in the fermentation products of wolfberry, tea, and beetroot are combined for exogenous anti-aging.

[0023] 4. Due to the synergistic fermentation of Lactobacillus plantarum AS1.555 and Bifidobacterium breve ATCC 15701, the preparation has an unexpected blood pressure lowering effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Figure 2 shows the Hyp content in the skin.

[0025] Figure 2 Figure 2 shows the MDA content in the skin.

[0026] Figure 3 A graph showing the H2O2 content in the skin.

[0027] Figure 4 This is a diagram of SOD activity in the skin.

[0028] Figure 5 This is a graph of CAT activity in the skin. DETAILED DESCRIPTION

[0029] The following describes the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the following embodiments and features in the embodiments can be combined with each other without conflict.

[0030] Example 1

[0031] This embodiment provides a human adipose stem cell preparation, the preparation process of which comprises:

[0032] S1. Activation and culture of adipose-derived stem cells (ADSCs): Take out cryopreserved primary adipose-derived stem cells (purchased from Wuhan Saios Biotechnology Co., Ltd., product number PC-016shp) from liquid nitrogen or -80°C freezer, quickly put the cryotube into a 37°C water bath and thaw rapidly until only a few ice crystals remain. Transfer the thawed cells into a centrifuge tube containing 10 times the volume of culture medium, i.e., LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin. Centrifuge at 1200 r / min for 5 min to remove the cryopreservation solution containing DMSO. Then resuspend the cells in LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin. 6 The cells were inoculated into T25 culture flasks at a cell density of 100 cells / ml and cultured in an incubator at 37°C and 5% CO2. After 72 hours of culture, the medium was replaced for the first time, and then the medium was replaced every 3 days until the primary cell confluence reached 80%. Then, the cells were digested with 0.25% trypsin and passaged at a ratio of 1:3.

[0033] S2. Preparation of adipose-derived stem cells (ADSCs) suspension: 2×10 3rd generation ADSCs with good growth conditions were taken. 7 1×10 6 The cells were inoculated into a T25 cell flask at a density of 2 × 10 cells / ml. When the cell confluence reached 70%, the cells were digested with 0.05% trypsin to form a cell suspension and counted. After centrifugation at 1000 r / min for 5 minutes, the cells were resuspended in 0.5 ml of PBS solution. The final cell concentration was adjusted to 2 × 10 6 / ml for standby use;

[0034] S3. Preparation of bacterial solution: The concentration is 3.1×10 9 cfu / ml of Lactobacillus plantarum AS1.555 and a concentration of 2.2×10 9 cfu / ml of Bifidobacterium breve ATCC 15701 bacterial solution for later use;

[0035] S4, the wolfberry, tea and beetroot were crushed and mixed, and then mixed with Bifidobacterium breve ATCC 15701 bacterial solution and deionized water in a mass ratio of 3:0.2:5, and then fermented in a cylinder, and the anaerobic fermentation was carried out at a temperature of 36°C for 6 hours; then Lactobacillus plantarum AS1.555 bacterial solution with the same mass as the Bifidobacterium breve ATCC 15701 bacterial solution was added, and aerobic fermentation was carried out at a temperature of 36°C for 8 hours. After the fermentation was completed, 3% hydrogen peroxide was added to inactivate Bifidobacterium breve ATCC 15701 and Lactobacillus plantarum AS1.555, and then centrifuged at 8000r / min for 10min, and the supernatant was collected. The obtained supernatant was sent to a steam sterilizer for sterilization at 121°C for 15min, and the sterilization program was: 10°C / min, raised to 121°C, maintained at 121°C for 15min, and cooled naturally after the program was completed;

[0036] S5, the adipose stem cell suspension prepared in step S2 was mixed with physiological saline containing 5% by volume of umbilical cord blood plasma to a concentration of 5×10 5 / ml, take 1ml of the adipose stem cell solution after adjusting the concentration and mix it with the sterilized fermentation supernatant prepared in step S4 with a volume fraction of 20% of the adipose stem cell solution, and place them in ampoules to obtain adipose stem cell injection.

[0037] Comparative Example 1: Except that the adipose stem cells in step S1 are replaced by bone marrow stem cells, the remaining steps are the same as those in Example 1. Bone marrow stem cells (sheep bone marrow mesenchymal stem cells) were purchased from Guangzhou Chaobo Technology Co., Ltd.

[0038] Comparative Example 2: Except that the adipose stem cell suspension is not added in step S5, the remaining steps are the same as those in Example 1.

[0039] Comparative Example 3: Except that fermentation supernatant is not added in step S5, the remaining steps are the same as those in Example 1.

[0040] Example 2

[0041] This embodiment provides a human adipose stem cell preparation, the preparation process of which comprises:

[0042] S1. Activation and culture of adipose-derived stem cells (ADSCs): Take out cryopreserved primary adipose-derived stem cells (purchased from Wuhan Saios Biotechnology Co., Ltd., product number PC-016shp) from liquid nitrogen or -80°C freezer, quickly put the cryotube into a 37°C water bath and thaw rapidly until only a few ice crystals remain. Transfer the thawed cells into a centrifuge tube containing 10 times the volume of culture medium, i.e., LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin. Centrifuge at 1500 r / min for 5 min to remove the cryopreservation solution containing DMSO. Then resuspend the cells in LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin. 6 The cells were inoculated into T25 culture flasks at a cell density of 100 cells / ml and cultured in an incubator at 37°C and 5% CO2. After 72 hours of culture, the medium was replaced for the first time, and then the medium was replaced every 3 days until the primary cell confluence reached 90%. Then, the cells were digested with 0.25% trypsin and passaged at a ratio of 1:3.

[0043] S2. Preparation of adipose-derived stem cells (ADSCs) suspension: 3×10 3rd generation ADSCs with good growth conditions were taken. 7 1×10 6 The cells were inoculated into a T25 flask at a density of 10 cells / ml. When the cell confluence reached 80%, they were digested with 0.05% trypsin to form a cell suspension and counted. After centrifugation at 1000 r / min for 5 minutes, they were resuspended in 0.5 ml of PBS solution. The final cell concentration was adjusted to 2×10 6 / ml for standby use;

[0044] S3. Preparation of bacterial solution: The concentration is 5.2×10 9 cfu / ml of Lactobacillus plantarum AS1.555 and a concentration of 4.1×10 9 cfu / ml of Bifidobacterium breve ATCC 15701 bacterial solution for later use;

[0045] S4, wolfberry, tea and beetroot are crushed and mixed, mixed with Bifidobacterium breve ATCC 15701 bacterial liquid and deionized water in a mass ratio of 5: 0.7: 10 and then mixed and fermented in a cylinder, anaerobic fermentation, temperature is 37 ° C, and fermentation time is 12 hours; and then add the plant lactobacillus AS1.555 bacterial liquid identical with the Bifidobacterium breve ATCC 15701 bacterial liquid quality, carry out aerobic fermentation, temperature is 37 ° C, fermentation time is 12 hours, after fermentation is complete, add 3% hydrogen peroxide and Bifidobacterium breve ATCC 15701 and plant lactobacillus AS1.555 are inactivated, then centrifuged at 8000r / min for 10min, collect fermentation supernatant, gained supernatant is sent to steam sterilizing pot sterilization 121 ° C sterilization 15min, sterilization program: 10 ° C / min, rise to 121 ° C, keep 15min at 121 ° C, naturally cool down after program ends;

[0046] S5, the adipose stem cell suspension prepared in step S2 was mixed with physiological saline containing 5% by volume of umbilical cord blood plasma to a concentration of 5×10 5 / ml, take 1ml of the adipose stem cell solution after adjusting the concentration and mix it with the fermentation supernatant prepared in step S4 with a volume fraction of 50% of the adipose stem cell solution, and put it in an ampoule to obtain an adipose stem cell injection.

[0047] Comparative Example 4: Except that in step S4, Bifidobacterium breve ATCC 15701 bacterial solution is not used for anaerobic fermentation, the remaining steps are the same as those in Example 2.

[0048] Comparative Example 5: Except that the Lactobacillus plantarum AS1.555 bacterial solution is not used for aerobic fermentation in step S4, the remaining steps are the same as those in Example 2.

[0049] Example 3

[0050] This embodiment provides a human adipose stem cell preparation, the preparation process of which comprises:

[0051] S1. Activation and culture of adipose-derived stem cells (ADSCs): Take out cryopreserved primary adipose-derived stem cells (purchased from Wuhan Saios Biotechnology Co., Ltd., product number PC-016shp) from liquid nitrogen or -80°C freezer, quickly put the cryotube into a 37°C water bath and thaw rapidly until only a few ice crystals remain. Transfer the thawed cells into a centrifuge tube containing 10 times the volume of culture medium, i.e., LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin. Centrifuge at 1500 r / min for 5 min to remove the cryopreservation solution containing DMSO. Then resuspend the cells in LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin. 6The cells were inoculated into T25 culture flasks at a cell density of 100 cells / ml and cultured in an incubator at 37°C and 5% CO2. After 72 hours of culture, the medium was replaced for the first time, and then the medium was replaced every 3 days until the primary cell confluence reached 85%. Then, the cells were digested with 0.25% trypsin and passaged at a ratio of 1:3.

[0052] S2. Preparation of adipose-derived stem cells (ADSCs) suspension: 2×10 3rd generation ADSCs with good growth conditions were taken. 7 1×10 6 The cells were inoculated into a T25 flask at a density of 10 cells / ml. When the cell confluence reached 80%, they were digested with 0.05% trypsin to form a cell suspension and counted. After centrifugation at 1000 r / min for 5 minutes, they were resuspended in 0.5 ml of PBS solution. The final cell concentration was adjusted to 2×10 6 / ml for standby use;

[0053] S3. Preparation of bacterial solution: The concentration is 4.1×10 9 cfu / ml of Lactobacillus plantarum AS1.555 bacterial solution and a concentration of 3.2×10 9 cfu / ml of Bifidobacterium breve ATCC 15701 bacterial solution for later use;

[0054] S4, the wolfberry, tea and beetroot were crushed and mixed, and then mixed with Bifidobacterium breve ATCC 15701 bacterial solution and deionized water in a mass ratio of 4:0.3:7, and then fermented in a cylinder, and the anaerobic fermentation was carried out at a temperature of 37°C for 8 hours; then Lactobacillus plantarum AS1.555 bacterial solution with the same mass as the Bifidobacterium breve ATCC 15701 bacterial solution was added, and aerobic fermentation was carried out at a temperature of 37°C for 12 hours. After the fermentation was completed, 3% hydrogen peroxide was added to inactivate Bifidobacterium breve ATCC 15701 and Lactobacillus plantarum AS1.555, and then centrifuged at 8000r / min for 10min, and the supernatant was collected. The obtained supernatant was sent to a steam sterilizer for sterilization at 121°C for 15min, and the sterilization program was: 10°C / min, raised to 121°C, maintained at 121°C for 15min, and cooled naturally after the program was completed;

[0055] S5, the adipose stem cell suspension prepared in step S2 was mixed with physiological saline containing 5% by volume of umbilical cord blood plasma to a concentration of 5×10 5 / ml, take 1ml of the adipose stem cell solution after adjusting the concentration and mix it with the fermentation supernatant prepared in step S4 with a volume fraction of 50% of the adipose stem cell solution, and put it in an ampoule to obtain an adipose stem cell injection.

[0056] Comparative Example 6: Except that Bifidobacterium breve ATCC 15701 in step S4 was replaced by Bifidobacterium breve ATCC 15698 (purchased from Beijing Biobo Biotechnology Co., Ltd., product number Bio-80099), the remaining steps were the same as those in Example 3.

[0057] Comparative Example 7: Except that Lactobacillus plantarum AS1.555 in step S4 is replaced by Lactobacillus plantarum CGMCC1.557 (purchased from Qingdao High-tech Industrial Park Haibo Biotechnology Co., Ltd., product number: HBJZ066), the remaining steps are the same as those in Example 3.

[0058] Example 4

[0059] Animal Experimentation:

[0060] Anti-aging experiment:

[0061] Ten healthy 3-month-old female Kunming mice weighing 50-60 grams; 110 healthy 20-month-old female Kunming mice weighing 250-300 grams. They were kept in an animal room at room temperature and humidity of about 55%, simulating the biological cycle of animals with alternating day and night (12h / 12h), and fed with sterile diet for 2 weeks. During the experiment, they were allowed to drink water and eat freely.

[0062] Mouse grouping:

[0063] Ten healthy 3-month-old female Kunming mice were used as the young control group; 110 healthy 20-month-old female Kunming mice were randomly divided into 11 groups, including 1 old control group of 10 mice, 3 embodiment groups (10 mice in each of the embodiment 1-3 groups, a total of 30 mice), and 7 comparative example groups (10 mice in each of the comparative example 1-7 groups, a total of 70 mice);

[0064] Dosage:

[0065] The young control group and the elderly control group were subcutaneously injected with medical glucose injection at a dosage of 0.25 ml / 100 g every day; the example group was subcutaneously injected with the adipose stem cell injection prepared in Examples 1-3 at a dosage of 0.25 ml / 100 g every day; the comparative example group was subcutaneously injected with the adipose stem cell injection prepared in Comparative Examples 1-7 at a dosage of 0.25 ml / 100 g every day; the administration was continued once a day for 30 days.

[0066] Source:

[0067] On the 31st day, 8% sodium sulfide solution was used to remove the hair on the back skin of all mice, with an area of ​​3cm×2cm. After all mice were killed by cervical dislocation, the full-thickness skin (excluding subcutaneous fat) of the back hair removal area was immediately removed. One piece of skin tissue was taken from the same position of each mouse in each group, wrapped with clean tin foil, clearly marked, put into a self-sealing bag, and frozen in a -20℃ freezer for the determination of various indicators.

[0068] Determination of different indicators of skin tissue:

[0069] Skin tissue homogenate preparation:

[0070] a. Take the skin tissue out of the -20℃ refrigerator, take 0.5g of each mouse skin tissue specimen, put them into glass dishes, cut the tissue pieces into pieces with surgical scissors, and then pour the cut skin tissue into a glass homogenizer tube.

[0071] b. Add 9 times the weight of each piece of skin into the homogenizer tube containing the minced skin tissue to prepare a skin slurry with a concentration of 10%. Place the homogenizer tube into the homogenizer to homogenize the tissue.

[0072] c. Slurry centrifugation: 4000rpm, centrifuge for 10min, retain the supernatant for measuring various indicators.

[0073] The obtained skin tissue homogenate was used to determine the Hyp content (μg / mgprot), MDA content (nmol / mgprot), H2O2 content (μmol / mgprot), SOD activity (NU / mgprot), and CAT activity (U / mgprot) in the skin tissue according to the instructions of the corresponding kits; among them, the hydroxyproline (Hyp) kit, malondialdehyde (MDA) kit, hydrogen peroxide (H2O2) kit, superoxide dismutase (SOD) kit, and catalase (CAT) kit were all purchased from Nanjing Jiancheng Bioengineering Institute.

[0074] Table 1

[0075]

[0076] Table 2

[0077]

[0078] Hyp is the most abundant amino acid in collagen and one of the unique amino acids in collagen. Other tissues contain almost no Hyp. Its content can be used as an important indicator to determine the content of collagen. Figure 1It can be seen that the Hyp content of aged skin is significantly reduced. In the embodiment group, the collagen content of aged skin can be increased by injecting adipose stem cells, while when bone marrow stem cells are used, the effect is not as good as adipose stem cells within 30 days. This is because adipose stem cells have lower immunogenicity, which reduces the immune rejection reaction when used allogeneically.

[0079] The free radical theory of aging proposed by Harman D believes that excessive free radicals induce oxidation reactions in organisms, damage the tissues and cells of organisms, and then cause aging. Free radicals are divided into reactive oxygen free radicals and reactive nitrogen free radicals. Reactive oxygen free radicals usually refer to H2O2, superoxide, singlet oxygen and hydroxyl free radicals. The ∙OH produced by H2O2 under certain conditions can damage unsaturated fatty acids in the cytoplasm, causing peroxidation reactions in the cytoplasm, causing cells to be damaged and produce substances such as MDA and ethane. When the free radical level increases, the activity of enzymes such as SOD and CAT in the body will change to fight against excessive free radicals. According to Table 1 and Figure 2 and Figure 3 It can be seen that the content of H2O2 and MDA in aging cells increased significantly, while the content of H2O2 and MDA decreased from the old state to the young state after treatment with the adipose stem cell injection prepared in the example group. This is because the growth factors produced by adipose stem cells can effectively repair cells. At the same time, the wolfberry polysaccharides, tea polyphenols and nicotinamide riboside obtained by the synergistic fermentation of wolfberry, tea and beetroot by Bifidobacterium breve ATCC 15701 and Lactobacillus plantarum AS1.555 have excellent antioxidant properties. At the same time, according to Table 2, Figure 4 and Figure 5 It can be seen that SOD and CAT are significantly reduced in aging skin. When there are a large number of free radicals in the skin, there is not enough SOD and CAT to remove the free radicals. After using the adipose stem cell injection prepared by the embodiment group, the repaired and regenerated skin cells can produce enough SOD and CAT enzymes to remove free radicals. At the same time, bifidobacterium breve ATCC 15701 and lactobacillus plantarum AS1.555 synergistically ferment wolfberry, tea and beetroot to obtain wolfberry polysaccharides, tea polyphenols and nicotinamide riboside and other substances can also help alleviate skin damage, relaxation and roughness caused by ultraviolet radiation, and can reduce the harmful peroxide content in the body to a certain extent. At the same time, according to the data of comparative examples 2 and 3 in Tables 1 and 2, anti-aging not only requires the generation of new cells and the repair of damaged cells, but also requires the intake of substances with antioxidant functions, which are used to remove excessive free radicals when the activity of enzymes such as SOD and CAT in the body is reduced to prevent skin aging.

[0080] Blood pressure lowering experiment:

[0081] 120 3-month-old C57BL / 6J male rats (purchased from Beijing Huafukang Biotechnology Co., Ltd.), weighing 180-200g, were adaptively raised in an SPF animal room. The feeding conditions were as follows: animals were free to eat and drink, the temperature was maintained at 23℃-25℃, the humidity was 55%±5%, and the day and night cycle was 12h per day. After 1 week of adaptive feeding, 10 rats were randomly selected as the normal group and raised normally. The remaining rats were modeled. Starting from the 8th day, the modeled rats were gavaged with L-nitroarginine (L-NNA) at 9:00 am every day, with a gavage volume of 490mg / kg / d. The normal group rats were gavaged with an equal volume of normal saline, and the modeling lasted for 28 consecutive days. During the intragastric administration, the blood pressure of the modeling group rats was measured every 7 days, that is, at 15:00 p.m. on the 7th, 14th, 21st and 28th day of modeling, using the BP-98A rat non-invasive blood pressure measurement system to measure the systolic pressure of the rat tail. Each rat was measured three times and the average value was calculated. When the average systolic pressure ≥180 mmHg, it indicated that the modeling was successful.

[0082] The rats with successful modeling were randomly divided into a model group, an example group (3 groups of examples 1-3 in total), and a comparative example group (7 groups of comparative examples 1-7 in total), with 10 rats in each group. The example group was injected with the adipose stem cell injection prepared in examples 1-3 at a volume of 0.25 ml / 100 g body weight every day; the comparative example group was injected with the adipose stem cell injection prepared in comparative examples 1-7 at a volume of 0.25 ml / 100 g body weight every day; the normal group and the model group were injected with an equal amount of 0.9% sodium chloride injection (normal saline injection) once a day for 8 consecutive weeks. During this period, the rats' body weight, food intake, heart rate, mental and activity status were regularly observed and recorded, and the changes in blood pressure were recorded. The pressure measurement method was the same as above.

[0083] Table 3

[0084]

[0085] According to the results of monitoring the blood pressure of rats in Table 3, the stem cell injection prepared by the present invention has an unexpected blood pressure lowering function, and the blood pressure of rats can return to normal after 56 days of intervention using the stem cell injection prepared by Examples 1-3. At the same time, according to the results of Comparative Example 3 in Table 3, it can be seen that whether the fermentation supernatant obtained by synergistically fermenting wolfberry, tea and beetroot with Bifidobacterium breve ATCC 15701 and Lactobacillus plantarum AS1.555 is added has a greater effect on the blood pressure of rats.

[0086] The above-mentioned embodiments only express the specific implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the protection scope of the present invention. It should be pointed out that, for those skilled in the art, without departing from the concept of the present invention, any other changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principle of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A process for preparing a human adipose stem cell preparation, characterized in that: The specific preparation method is as follows: S1. Activation and culture of adipose-derived stem cells (ADSCs): Take out the frozen adipose-derived stem cells from liquid nitrogen or -80℃ freezer, quickly put the cryotube into a 37℃ water bath to thaw, transfer the thawed cells into a centrifuge tube containing 5-10 times the volume of the culture medium, i.e. LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin, centrifuge at 1200-1500 r / min for 5 min, then resuspend the cells in LG-DMEM culture medium containing 20% ​​fetal bovine serum and 100 U / mL streptomycin, and centrifuge at 3×10 6 -4×10 6 The cells were inoculated into T25 culture flasks at a cell density of 100 cells / mL and cultured in an incubator at 37°C and 5% CO2. After 72 hours of culture, the medium was replaced for the first time. Thereafter, the medium was replaced every 3 days until the primary cell confluence reached 80%-90%. The cells were then digested with 0.25% trypsin and passaged at a ratio of 1:

3. S2. Preparation of adipose-derived stem cells (ADSCs) suspension: 1×10 6 The cells were inoculated into T25 flasks at a density of 10 cells / mL. When the cell confluence reached 70-80%, they were digested with 0.05% trypsin to form a cell suspension and counted. After centrifugation at 1000 r / min for 5 minutes, they were resuspended in 0.5 mL of PBS solution and the final cell concentration was adjusted to 2×10 6 / mL for standby use; S3. Preparation of bacterial solution: The concentration is 3.1×10 9 -5.2×10 9 cfu / mL of Lactobacillus plantarum AS1.555 and a concentration of 2.2×10 9 -4.1×10 9 cfu / mL of Bifidobacterium breve ATCC 15701 bacterial solution for later use; S4, the wolfberry, tea and beetroot are crushed and mixed, and then mixed with Bifidobacterium breve ATCC 15701 bacterial solution and deionized water in a mass ratio of 3-5:0.2-0.7:5-10, and then fermented in a cylinder, and the anaerobic fermentation is carried out at a temperature of 35-37°C and a fermentation time of 6-12 hours; then the plant lactobacillus AS1.555 bacterial solution with the same mass as the Bifidobacterium breve ATCC 15701 bacterial solution is added, and aerobic fermentation is carried out at a temperature of 35-37°C and a fermentation time of 6-12 hours. After the fermentation is completed, 3% hydrogen peroxide is added to inactivate Bifidobacterium breve ATCC 15701 and Lactobacillus plantarum AS1.555, and then centrifuged at 8000r / min for 10min, and the supernatant is collected. The obtained supernatant is sent to a steam sterilizer for sterilization at 121°C for 15min, and the sterilization program is: 10°C / min, raised to 121°C, kept at 121°C for 15min, and cooled naturally after the program ends; S5, the adipose stem cell suspension prepared in step S2 was mixed with physiological saline containing 5% umbilical cord blood plasma to a concentration of 5×10 5 / mL, take 1mL of the adipose stem cell solution after adjusting the concentration, and mix it with the fermentation supernatant prepared in step S4 with a volume fraction of 20-50% of the adipose stem cell solution, and place it in an ampoule to obtain an adipose stem cell injection.

2. A process for preparing a human adipose stem cell preparation according to claim 1, characterized in that: The adipose stem cells cryopreserved in step S1 are primary sheep adipose stem cells.

3. A process for preparing a human adipose stem cell preparation according to claim 1, characterized in that: In step S1, 4×10 6 The cells were seeded into T25 culture flasks at a cell density of 10 cells / mL.

4. A process for preparing a human adipose stem cell preparation according to claim 3, characterized in that: The concentration prepared in step S3 is 4.1×10 9 cfu / mL of Lactobacillus plantarum AS1.555 bacterial liquid.

5. A process for preparing a human adipose stem cell preparation according to claim 4, characterized in that: The concentration prepared in step S3 is 3.2×10 9 cfu / mL of Bifidobacterium breve ATCC 15701 bacterial solution.

6. A process for preparing a human adipose stem cell preparation according to claim 5, characterized in that: In the step S4, wolfberry, tea leaves and beetroot are crushed and mixed in a mass ratio of 1:1:

2.

7. The preparation obtained by the process for preparing a human adipose stem cell preparation according to any one of claims 1 to 6.

Citation Information

Patent Citations

  • Composition containing bifidobacterium extract for stem cell performance increasing of fat source stem cell and for skin cell proliferation

    CN102477410A

  • Injection gel containing submicron hyaluronic acid microspheres and preparation method thereof

    CN102813961A

  • Preparation method and application of human adipose-derived stem cells for improving skin repairing function

    CN105154407A

  • Stem cell gel precursor composition for repairing skin injury and tissue engineering composition using box and application thereof

    CN111359010A

  • Adipose-derived stem cell growth factor extract as well as preparation method and application thereof

    CN113957040A